TELMISARTAN AND HYDROCHLOROTHIAZIDE

Post-LOE

telmisartan and hydrochlorothiazide

Aurobindo Pharma

ANDAORALTABLET

Approved

Feb 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

TELMISARTAN AND HYDROCHLOROTHIAZIDE (telmisartan and hydrochlorothiazide) by Aurobindo Pharma is angiotensin 2 receptor antagonists [moa]. Approved for thiazide diuretic [epc]. First approved in 2014.

Drug data last refreshed 21h ago

Mechanism of Action

Angiotensin 2 Receptor Antagonists

Pharmacologic Class:

Thiazide Diuretic

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT02248129N/ACompleted

Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide

Started Apr 2006

4,255 enrolled

Hypertension

NCT00153049Phase 2Completed

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

Started Jun 2004

583 enrolled

Hypertension

Company

Worked on TELMISARTAN AND HYDROCHLOROTHIAZIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.